Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NRAS G12V”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05726864
What this trial is testing

ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaColorectal CancerKRAS G12D+11 more
Elicio Therapeutics 158
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Testing effectiveness (Phase 2)Looking for participantsNCT03190941
What this trial is testing

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Who this might be right for
Pancreatic CancerGastric CancerGastrointestinal Cancer+2 more
National Cancer Institute (NCI) 110
Testing effectiveness (Phase 2)Active Not RecruitingNCT05585320
What this trial is testing

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorPancreatic AdenocarcinomaMalignant Melanoma (Cutaneous)+1 more
Immuneering Corporation 209
Not applicableAvailableNCT07083479
What this trial is testing

Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma

Who this might be right for
Pancreatic Ductal AdenocarcinomaKRAS G12DKRAS G12V+12 more
Elicio Therapeutics